Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Babaodan in the preparation of medicines for preventing non-alcoholic fatty liver

A non-alcoholic, fatty liver technology, applied in the field of Babao Dan in the preparation of drugs for the prevention of non-alcoholic fatty liver disease, can solve the problems of liver toxicity, lack of standardized and completely effective treatment methods, etc., and achieve definite curative effect , good development prospects, and remarkable effects

Active Publication Date: 2021-07-16
XIAMEN TRADITIONAL CHINESE MEDICINE +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently, Western medicine has no effective drugs for the treatment of nonalcoholic fatty liver disease. Drugs that regulate blood lipids are mainly used as adjuvant therapy, and there is still a lack of standardized and completely effective treatment methods. Some drugs can cause lipid deposition in the blood. in the liver and is toxic to the liver itself

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Babaodan in the preparation of medicines for preventing non-alcoholic fatty liver
  • Use of Babaodan in the preparation of medicines for preventing non-alcoholic fatty liver
  • Use of Babaodan in the preparation of medicines for preventing non-alcoholic fatty liver

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Embodiment 1 body weight and liver index

[0018] Weigh and record the mice every week, observe the body weight of the mice in each group, and compare the changes in body weight before and after the drug administration. ), body weight growth rate (%)=(final weight-initial weight) / initial weight×100%.

[0019] Determination of LEE'S index value: Accurately measure body length (length from nose to anus) and tail length under anesthesia, and then calculate LEE'S INDEX value according to the following formula:

[0020] LEE'S INDEX=weight (g)^(1 / 3)*1000 / body length (cm)

[0021] After the above experiment was over, the liver was quickly taken out and weighed to calculate the liver index (liver weight / body weight*100%).

[0022] See the experimental results figure 1 And Table 1, BBD can significantly inhibit body weight gain and reduce liver index in C57 mice.

[0023] Table 1 shows the data of body weight, Lee's index and liver index in the process of non-alcoholic lipog...

Embodiment 2

[0026] Embodiment 2 fat content

[0027] After the experiment of the growth index in Example 1 was completed, the fat accumulation around the liver was dissected to observe the fat accumulation, and the weight of the fat was weighed.

[0028] See the experimental results figure 2 , Compared with the normal group, the body fat content of the mice in the HFD group was significantly increased, and the fat content in the BBD group was significantly reduced after intragastric administration.

Embodiment 3

[0029] Embodiment 3 serological examination

[0030] After the experiment of the growth index in Example 1 was finished, fasted for 6 hours, blood was taken from the mice, centrifuged at 3000r / min for 10min, the separated serum was to be tested, and serum cholesterol (TC), triglyceride (TG), high-density lipoprotein were measured (HDL), low-density lipoprotein (LDL), aspartate aminotransferase (AST), blood glucose (Glu) levels.

[0031] See the experimental results image 3 , the content of each index in the serum of mice in the HFD group was significantly increased, and the TG content in the BBD group was significantly decreased after intragastric administration, and the TC content was slightly decreased. Babaodan can also reduce the elevated LDL, Glu and AST caused by fatty liver, but has no significant effect on reducing the elevated HDL.

[0032] AST is aspartate aminotransferase, which mainly exists in the mitochondria of liver cells. When the liver is severely necrotic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides the use of Babaodan in the preparation of medicines for preventing non-alcoholic fatty liver. Pharmacological experiments have found that Babaodan has a significant effect in preventing non-alcoholic fatty liver disease. Therefore, Babaodan can be used to prepare non-alcoholic fatty liver medicine, and has a good prospect for development and use.

Description

technical field [0001] The invention belongs to the field of new indications of medicines, and specifically relates to the use of Babaodan in the preparation of medicines for preventing non-alcoholic fatty liver disease. Background technique [0002] At present, the prevalence of non-alcoholic fatty liver disease (NAFLD) in the global general population is as high as 20% to 30%, significantly exceeding the incidence of hepatitis B, hepatitis C and alcoholic liver disease. become the most common liver disease. The disease used to be common in western countries, but with the improvement of living standards in my country and the changes in lifestyle and diet, the prevalence rate in China is on the rise in recent years. [0003] Nonalcoholic fatty liver disease is a clinicopathological syndrome mainly characterized by excessive fat deposition in liver cells caused by alcohol and other definite liver damage factors, and metabolic stress liver injury closely related to insulin re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/258A61P1/16A61K35/413A61K35/583A61K35/32A61K35/618A61K35/55
Inventor 刘彦君卫立辛沈锋叶冠韩志鹏赵亚红安泳潼杨雪詹志学赖志成姜京花梁磊于洋
Owner XIAMEN TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com